We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valentis has initiated patient dosing on schedule in a Phase IIb clinical trial
to evaluate the safety and efficacy of VLTS-934 in patients with peripheral
arterial disease.
Join FDAnews Wednesday, May 4 for an audioconference on "Combating
Counterfeit Drugs: Keep Illegal Knock-Offs From Knocking Off Your Earnings."
Learn concrete steps you can take to protect your market share and minimize
your legal exposure. Benefit directly from the expertise of Chris Michie,
a noted attorney and authority on counterfeit drugs, the gray market and illegal
product sales over the internet.
ISTA Pharmaceuticals has received FDA approval for Xibrom, a topical, twice-daily,
nonsteroidal anti-inflammatory solution intended to treat ocular inflammation
following cataract surgery.
The FDA has approved Millennium Pharmaceuticals' supplemental new drug application
for Velcade, clearing the way for the drug to be prescribed to patients with
multiple myeloma (MM) who have received at least one prior therapy.
Nymox Pharmaceutical's U.S. and global patent rights and prospects for the use
of statin drugs for treating, preventing or reducing the risk of Alzheimer's
disease in patients at risk for the disease have been strongly bolstered by
newly published study data showing growing acceptance of the drugs' indications
for patients at risk for dementia.
AVI BioPharma has announced the publication of two articles in the April 2005
Journal of Virology describing preclinical studies in which its NEUGENE
antisense drugs were used to inhibit dengue virus and West Nile virus (WNV)
infection.
Human Genome Sciences has begun dosing patients in a Phase I clinical trial
to evaluate the safety, tolerability and pharmacology of CCR5 mAb in patients
who are infected with HIV-1, the retrovirus that causes AIDS.
Aeolus Pharmaceuticals has announced interim results for its Phase I, escalating
single-dose study to evaluate the safety, tolerability and pharmacokinetics
of AEOL 10150 administered by subcutaneous injection in patients with amyotrophic
lateral sclerosis (ALS).
An independent data monitoring committee (IDMC) has recommended the continuation
of Corautus Genetics' GENASIS trial based on an interim safety analysis.